Fabio Candotti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/669596/publications.pdf

Version: 2024-02-01

182 papers	10,786 citations	38742 50 h-index	33894 99 g-index
210 all docs	210 docs citations	210 times ranked	12095 citing authors

#	Article	IF	Citations
1	Signaling networks in B cell development and related therapeutic strategies. Journal of Leukocyte Biology, 2022, 111, 877-891.	3.3	2
2	Critical role of WASp in germinal center tolerance through regulation of B cell apoptosis and diversification. Cell Reports, 2022, 38, 110474.	6.4	4
3	Common Variable Immunodeficiency in a Carrier of the ADA2 R169Q Variant: Coincidence or Causality?. Journal of Clinical Immunology, 2022, , 1.	3.8	1
4	Der primÃre Immundefekt â€“ Ein praktischer Leitfaden fÃ¼r den Kinderarzt. Paediatrica, 2022, 33, .	0.1	0
5	ImmunodÃ©ficience primaire - guide pratique pour les pÃ©diatres. Paediatrica, 2022, 33, .	0.0	0
6	Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the <scp>TPP2</scp> gene. Clinical Genetics, 2021, 99, 780-788.	2.0	4
7	Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. New England Journal of Medicine, 2021, 384, 2002-2013.	27.0	122
8	Transcriptomic Signature Differences BetweenÂSARS-CoV-2 and Influenza Virus Infected Patients. Frontiers in Immunology, 2021, 12, 666163.	4.8	27
9	Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Blood, 2021, 138, 1304-1316.	1.4	28
10	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Journal of Clinical Immunology, 2021, 41, 1633-1647.	3.8	43
11	Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity. Frontiers in Immunology, 2021, 12, 725587.	4.8	7
12	Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy. Biology of Blood and Marrow Transplantation, 2020, 26, 1819-1827.	2.0	8
13	Adenosine Deaminase (ADA)â€“Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry. Journal of Clinical Immunology, 2020, 40, 1124-1131.	3.8	19
14	Severe combined immune deficiency. , 2020, , 153-205.		7
15	Intra-uterine growth restriction induced by maternal low-protein diet causes long-term alterations of thymic structure and function in adult male rat offspring. British Journal of Nutrition, 2020, 123, 892-900.	2.3	8
16	Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. Journal of Clinical Immunology, 2019, 39, 476-485.	3.8	85
17	Gene therapy for Wiskott-Aldrich syndrome: here to stay. Lancet Haematology,the, 2019, 6, e230-e231.	4.6	6
18	A model for reticular dysgenesis shows impaired sensory organ development and hair cell regeneration linked to cellular stress. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	4

#	Article	IF	Citations
19	Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort. Blood, 2019, 134, 3345-3345.	1.4	12
20	Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome. Journal of Clinical Immunology, 2018, 38, 13-27.	3.8	156
21	Gene therapy for the treatment of adenosine deaminase-deficient severe combined immune deficiency. Expert Opinion on Orphan Drugs, 2017, 5, 477-485.	0.8	0
22	Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients. Blood, 2017, 129, 2624-2635.	1.4	27
23	Clinical efficacy of gene-modified stem cells in adenosine deaminaseâ€“deficient immunodeficiency. Journal of Clinical Investigation, 2017, 127, 1689-1699.	8.2	70
24	Combined T Cell and B Cell Deficiency â€“ SCID Forms: T â˜ B +. , 2016, , 360-368.		0
25	280. Lentiviral-Mediated Gene Therapy Restores B Cell Homeostasis and Tolerance in Wiskott-Aldrich Syndrome Patients. Molecular Therapy, 2016, 24, S112.	8.2	0
26	N-WASP is required for B-cellâ€“mediated autoimmunity in Wiskott-Aldrich syndrome. Blood, 2016, 127, 216-220.	1.4	24
27	The long terminal repeat negative control region is a critical element for insertional oncogenesis after gene transfer into hematopoietic progenitors with Moloney murine leukemia viral vectors. Gene Therapy, 2016, 23, 815-818.	4.5	2
28	Type I interferonopathies in pediatric rheumatology. Pediatric Rheumatology, 2016, 14, 35.	2.1	104
29	FOXP3+ Tregs require WASP to restrain Th2-mediated food allergy. Journal of Clinical Investigation, 2016, 126, 4030-4044.	8.2	53
30	Advances of gene therapy for primary immunodeficiencies. F1000Research, 2016, 5, 310.	1.6	14
31	Detection of Reactive Oxygen Species Using MitoSOX and CellROX in Zebrafish. Bio-protocol, 2016, 6, .	0.4	5
32	Wiskott-Aldrich Syndrome: A Retrospective Study on 575 Patients Analyzing the Impact of Splenectomy, Stem Cell Transplantation, or No Definitive Treatment on Frequency of Disease-Related Complications and Physician-Perceived Quality of Life. Blood, 2016, 128, 366-366.	1.4	2
33	Autologous Transplant/Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency. Biology of Blood and Marrow Transplantation, 2015, 21, S102.	2.0	1
34	30. Phase II Clinical Trial of Gene Therapy for Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA-SCID) Using a Î³-Retroviral Vector. Molecular Therapy, 2015, 23, S13-S14.	8.2	1
35	C-8. Immunological and Metabolic Correction After Lentiviral Vector Gene Therapy for ADA Deficiency. Molecular Therapy, 2015, 23, S102-S103.	8.2	8
36	240. Stable and Clinically Benign Clonal Dominance in an ADA-SCID Patient Treated With Retroviral Gene Therapy. Molecular Therapy, 2015, 23, S94.	8.2	0

#	Article	IF	Citations
37	Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. Orphanet Journal of Rare Diseases, 2015, 10, 159.	2.7	10
38	NBAS mutations cause a multisystem disorder involving bone, connective tissue, liver, immune system, and retina. American Journal of Medical Genetics, Part A, 2015, 167, 2902-2912.	1.2	66
39	Assessment of Immature Platelet Fraction in the Diagnosis of WiskottÃ¢â‚¬â€œAldrich Syndrome. Frontiers in Pediatrics, 2015, 3, 49.	1.9	15
40	Identification of type I interferonopathies using blood interferon signature: the experience of a pediatric rheumatology center. Pediatric Rheumatology, 2015, 13, .	2.1	1
41	Individualized Iterative Phenotyping for Genome-wide Analysis of Loss-of-Function Mutations. American Journal of Human Genetics, 2015, 96, 913-925.	6.2	66
42	Reticular dysgenesisâ€“associated AK2 protects hematopoietic stem and progenitor cell development from oxidative stress. Journal of Experimental Medicine, 2015, 212, 1185-1202.	8.5	49
43	Outcomes in Two Japanese Adenosine Deaminase-Deficiency Patients Treated by Stem Cell Gene Therapy with No Cytoreductive Conditioning. Journal of Clinical Immunology, 2015, 35, 384-398.	3.8	25
44	Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome. Journal of Experimental Medicine, 2015, 212, 1663-1677.	8.5	67
45	Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Journal of Allergy and Clinical Immunology, 2015, 136, 1401-1404.e3.	2.9	25
46	In vitro functional correction of Hermanskyâ€“Pudlak Syndrome type-1 by lentiviral-mediated gene transfer. Molecular Genetics and Metabolism, 2015, 114, 62-65.	1.1	10
47	Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. Journal of Clinical Investigation, 2015, 125, 3941-3951.	8.2	43
48	Age-Dependent Defects of Regulatory B Cells in Wiskott-Aldrich Syndrome Gene Knockout Mice. PLoS ONE, 2015, 10, e0139729.	2.5	10
49	Reticular dysgenesisâ€“associated AK2 protects hematopoietic stem and progenitor cell development from oxidative stress. Journal of Cell Biology, 2015, 210, 2102OIA141.	5.2	0
50	Severe Combined Immunodeficiencies. , 2014, , 87-141.		1
51	Molecular and phenotypic abnormalities of B lymphocytes in patients with Wiskott-Aldrich syndrome. Journal of Allergy and Clinical Immunology, 2014, 133, 896-899.e4.	2.9	28
52	Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases. International Journal of Hematology, 2014, 99, 383-392.	1.6	24
53	Primary Immune Deficiency Treatment Consortium (PIDTC) report. Journal of Allergy and Clinical Immunology, 2014, 133, 335-347.e11.	2.9	65
54	Activated STING in a Vascular and Pulmonary Syndrome. New England Journal of Medicine, 2014, 371, 507-518.	27.0	1,074

#	Article	IF	Citations
55	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine, 2014, 370, 911-920.	27.0	687
56	Nuclear Role of WASp in Gene Transcription Is Uncoupled from Its ARP2/3-Dependent Cytoplasmic Role in Actin Polymerization. Journal of Immunology, 2014, 193, 150-160.	0.8	57
57	Actionable Diagnosis of Neuroleptospirosis by Next-Generation Sequencing. New England Journal of Medicine, 2014, 370, 2408-2417.	27.0	760
58	Cation Leak in Red Blood Cells of Patients with Wiskott-Aldrich Syndrome Leads to Non-Immunologic Hemolysis. Blood, 2014, 124, 1338-1338.	1.4	0
59	What's the 'Skinny' on Microbiome? Interplay of Immune Cells, Microbes, and Skin Barrier in Health and Disease. Blood, 2014, 124, SCI-46-SCI-46.	1.4	0
60	Elevated IgE and atopy in patients treated for early-onset ADA-SCID. Journal of Allergy and Clinical Immunology, 2013, 132, 1444-1446.e5.	2.9	22
61	The altered landscape of the human skin microbiome in patients with primary immunodeficiencies. Genome Research, 2013, 23, 2103-2114.	5.5	236
62	Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Journal of Allergy and Clinical Immunology, 2013, 131, 587-590.e3.	2.9	14
63	Platelets from WAS patients show an increased susceptibility toex vivophagocytosis. Platelets, 2013, 24, 288-296.	2.3	19
64	A Novel Function of RNAs Arising From the Long Terminal Repeat of Human Endogenous Retrovirus 9 in Cell Cycle Arrest. Journal of Virology, 2013, 87, 25-36.	3.4	22
65	Peptide library-based evaluation of T-cell receptor breadth detects defects in global and regulatory activation in human immunologic diseases. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8164-8169.	7.1	5
66	Efficient Methods for Targeted Mutagenesis in Zebrafish Using Zinc-Finger Nucleases: Data from Targeting of Nine Genes Using CompoZr or CoDA ZFNs. PLoS ONE, 2013, 8, e57239.	2.5	58
67	Immunodeficiency Due to Defects of Purine Metabolism. , 2013, , 188-230.		6
68	Gene Therapy Model of X-linked Severe Combined Immunodeficiency Using a Modified Foamy Virus Vector. PLoS ONE, 2013, 8, e71594.	2.5	6
69	Negative Control Region Is a Critical Element Of Insertional Oncogenesis After Gene Transfer Into Hematopoietic Progenitors With Moloney Murine Leukemia Viruses. Blood, 2013, 122, 164-164.	1.4	0
70	AK2 Deficiency In Zebrafish Recapitulates Human Reticular Dysgenesis, An Autosomal Recessive Form Of Severe Combined Immunodeficiency. Blood, 2013, 122, 2416-2416.	1.4	0
71	Severe Combined Immunodeficiency and Combined Immunodeficiency Due to Cytokine Signaling Defects (IL2RG, JAK3, IL7R, IL2RA, JAK3 and STAT5B). , 2013, , 134-155.		1
72	Foamy Virus Vector-mediated Gene Correction of a Mouse Model of Wiskottâ€“Aldrich Syndrome. Molecular Therapy, 2012, 20, 1270-1279.	8.2	24

#	Article	IF	Citations
73	Gene therapy for adenosine deaminaseâ€“deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood, 2012, 120, 3635-3646.	1.4	222
74	B cellâ€“intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood, 2012, 119, 2819-2828.	1.4	99
75	Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminaseâ€“deficient severe combined immune deficiency. Journal of Allergy and Clinical Immunology, 2012, 129, 762-769.e1.	2.9	64
76	Development of IgA nephropathy-like glomerulonephritis associated with Wiskottâ€“Aldrich syndrome protein deficiency. Clinical Immunology, 2012, 142, 160-166.	3.2	17
77	Analysis of Risk and Mechanism of Insertional Oncogenesis After Gene Transfer Into Hematopoietic Progenitors with Integrating Viral Vectors. Blood, 2012, 120, 2049-2049.	1.4	0
78	Adenylate Kinase 2 Regulates Zebrafish Primitive and Definitive Hematopoiesis. Blood, 2012, 120, 1208-1208.	1.4	0
79	Measurement of Proliferative Responses of Cultured Lymphocytes. Current Protocols in Immunology, 2011, 94, Unit7.10.	3.6	39
80	Defective inhibition of B-cell proliferation by Wiskott-Aldrich syndrome protein-deficient regulatory T cells. Blood, 2011, 117, 6608-6611.	1.4	20
81	Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood, 2011, 118, 2688-2694.	1.4	45
82	Somatic Mosaicism Caused by Monoallelic Reversion of a Mutation in T Cells of a Patient with ADAâ€SCID and the Effects of Enzyme Replacement Therapy on the Revertant Phenotype. Scandinavian Journal of Immunology, 2011, 74, 471-481.	2.7	13
83	Platelets From WAS Patients Are More Susceptible Than Controls to Phagocytosis by Activated THP-1 Cells. Blood, 2011, 118, 2222-2222.	1.4	6
84	Comparison of Immortalization Potential of Gamma-Retroviral, Lentiviral and Foamy Virus Gene Transfer Vectors. Blood, 2011, 118, 3116-3116.	1.4	0
85	Characterization of AK2 Gene Function in Zebrafish Hematopoiesis. Blood, 2011, 118, 2185-2185.	1.4	0
86	Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-Aldrich syndrome protein. Blood, 2010, 116, 740-747.	1.4	48
87	Somatic mosaicism in the Wiskottâ€“Aldrich syndrome: Molecular and functional characterization of genotypic revertants. Clinical Immunology, 2010, 135, 72-83.	3.2	35
88	Nuclear Role of WASp in the Pathogenesis of Dysregulated T _H 1 Immunity in Human Wiskott-Aldrich Syndrome. Science Translational Medicine, 2010, 2, 37ra44.	12.4	109
89	Mosaicismâ€”Switch or Spectrum?. Science, 2010, 330, 46-47.	12.6	13
90	Self-inactivating Retroviral Vector-mediated Gene Transfer Induces Oncogene Activation and Immortalization of Primary Murine Bone Marrow Cells. Molecular Therapy, 2009, 17, 1910-1918.	8.2	29

#	Article	IF	Citations
91	Revertant somatic mosaicism in the Wiskottâ€“Aldrich syndrome. Immunologic Research, 2009, 44, 127-131.	2.9	47
92	Human adenylate kinase 2 deficiency causes a profound hematopoietic defect associated with sensorineural deafness. Nature Genetics, 2009, 41, 106-111.	21.4	198
93	Improving cellular therapy for primary immune deficiency diseases: Recognition, diagnosis, and management. Journal of Allergy and Clinical Immunology, 2009, 124, 1152-1160.e12.	2.9	110
94	Gene Therapy Fulfilling Its Promise. New England Journal of Medicine, 2009, 360, 518-521.	27.0	88
95	How I treat ADA deficiency. Blood, 2009, 114, 3524-3532.	1.4	206
96	Reduced Number of Dense Bodies and Reduced Serotonin Content in Platelets of Patients with Wiskott-Aldrich Syndrome.. Blood, 2009, 114, 1321-1321.	1.4	1
97	Measurement of Proliferative Responses of Cultured Lymphocytes. Current Protocols in Immunology, 2008, 82, Unit 7.10.1-7.10.24.	3.6	15
98	Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome. Blood, 2008, 111, 5064-5067.	1.4	30
99	Somatic mosaicism in primary immune deficiencies. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 510-514.	2.3	56
100	Recent advances in gene therapy for severe congenital immunodeficiency diseases. Current Opinion in Hematology, 2008, 15, 375-380.	2.5	34
101	Gene transfer therapy of immunologic diseases. , 2008, , 1281-1292.		0
102	Dermatofibrosarcoma Protuberans in 3 Patients with ADA-SCID. Blood, 2008, 112, 4833-4833.	1.4	0
103	Human Adenylate Kinase 2 Deficiency Causes a Profound Haematopoietic Defect Associated with Sensorineural Deafness. Blood, 2008, 112, lba-2-lba-2.	1.4	2
104	Immune Responses to Gene-Modified T Cells. Current Gene Therapy, 2007, 7, 361-368.	2.0	11
105	Structure-Function Analysis of the WIP Role in T Cell Receptor-stimulated NFAT Activation. Journal of Biological Chemistry, 2007, 282, 30303-30310.	3.4	22
106	Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report. Blood, 2007, 109, 503-506.	1.4	36
107	Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood, 2007, 110, 501-508.	1.4	51
108	Cartilage hair hypoplasia mutations that lead to RMRP promoter inefficiency or RNA transcript instability. American Journal of Medical Genetics, Part A, 2007, 143A, 2675-2681.	1.2	30

#	Article	IF	Citations
109	Impaired in vitro regulatory T cell function associated with Wiskottâ€“Aldrich syndrome. Clinical Immunology, 2007, 124, 41-48.	3.2	95
110	Comparative Results of Gene Therapy for Adenosine Deaminase Deficiency with or without PEG-ADA Withdrawal and Myelosuppressive Chemotherapy.. Blood, 2007, 110, 501-501.	1.4	2
111	X-SCID transgene leukaemogenicity. Nature, 2006, 443, E5-E6.	27.8	144
112	The expression of Wiskott-Aldrich syndrome protein (WASP) is dependent on WASP-interacting protein (WIP). International Immunology, 2006, 19, 185-192.	4.0	34
113	Lessons from the Wiskottâ€“Aldrich Syndrome. New England Journal of Medicine, 2006, 355, 1759-1761.	27.0	39
114	Functional Interaction of Common Î³-Chain and Growth Hormone Receptor Signaling Apparatus. Journal of Immunology, 2006, 177, 6889-6895.	0.8	17
115	Analysis of T-cell repertoire diversity in Wiskott-Aldrich syndrome. Blood, 2005, 106, 3895-3897.	1.4	38
116	Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunological Reviews, 2005, 203, 127-142.	6.0	126
117	CXCL12 Signaling Is Independent of Jak2 and Jak3. Journal of Biological Chemistry, 2005, 280, 17408-17414.	3.4	40
118	Retroviral-mediated gene transfer restores IL-12 and IL-23 signaling pathways in T cells from IL-12 receptor Î²1-deficient patients. Molecular Therapy, 2004, 9, 895-901.	8.2	11
119	A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers. Journal of Virological Methods, 2004, 118, 61-67.	2.1	6
120	Jak3 and the pathogenesis of severe combined immunodeficiency. Molecular Immunology, 2004, 41, 727-737.	2.2	109
121	Engraftment Potential of Human Amnion and Chorion Cells Derived from Term Placenta. Transplantation, 2004, 78, 1439-1448.	1.0	318
122	Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. Blood, 2004, 103, 676-678.	1.4	50
123	A novel form of complete IL-12/IL-23 receptor Â1 deficiency with cell surface-expressed nonfunctional receptors. Blood, 2004, 104, 2095-2101.	1.4	103
124	Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family. Blood, 2004, 104, 1270-1272.	1.4	32
125	High incidence of lymphomas in a subgroup of wiskott-aldrich syndrome patients. British Journal of Haematology, 2003, 121, 529-530.	2.5	33
126	Evidence That the Mouse 3â€²Îº Light Chain Enhancer Confers Position-Independent Transgene Expression in T- and B-Lineage Cells. Human Gene Therapy, 2003, 14, 1753-1764.	2.7	0

#	Article	IF	Citations
127	American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Molecular Therapy, 2003, 8, 180-187.	8.2	147
128	SLAM-associated Protein Deficiency Causes Imbalanced Early Signal Transduction and Blocks Downstream Activation in T Cells from X-linked Lymphoproliferative Disease Patients. Journal of Biological Chemistry, 2003, 278, 29593-29599.	3.4	24
129	Primary immunodeficiencies and the rheumatologist. Current Opinion in Rheumatology, 2003, 15, 413-416.	4.3	3
130	Autoimmunity in Wiskott-Aldrich syndrome. Current Opinion in Rheumatology, 2003, 15, 446-453.	4.3	89
131	Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood, 2003, 101, 2563-2569.	1.4	203
132	In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals. Blood, 2003, 102, 843-848.	1.4	37
133	Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. Journal of Clinical Investigation, 2003, 111, 1389-1397.	8.2	69
134	Jak3 and the Pathogenesis of Severe Combined Immunodeficiency. , 2003, , 623-636.		0
135	Immune Response to Fetal Calf Serum by Two Adenosine Deaminase-Deficient Patients After T Cell Gene Therapy. Human Gene Therapy, 2002, 13, 1605-1610.	2.7	162
136	Retrovirus-Mediated WASP Gene Transfer Corrects Wiskott-Aldrich Syndrome T-Cell Dysfunction. Human Gene Therapy, 2002, 13, 1039-1046.	2.7	52
137	Flow Cytometry Analysis of Adenosine Deaminase (ADA) Expression: A Simple and Reliable Tool for the Assessment of ADA-Deficient Patients Before and After Gene Therapy. Human Gene Therapy, 2002, 13, 425-432.	2.7	13
138	Cytokines and their role in lymphoid development, differentiation and homeostasis. Current Opinion in Allergy and Clinical Immunology, 2002, 2, 495-506.	2.3	81
139	Reconstitution of lymphoid development and function in ZAP-70â€“deficient mice following gene transfer into bone marrow cells. Blood, 2002, 100, 1248-1256.	1.4	23
140	Gene Therapy in Infants with Severe Combined Immunodeficiency. BioDrugs, 2002, 16, 229-239.	4.6	12
141	Pharmacokinetics and organ distribution of N -methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene. Cancer Chemotherapy and Pharmacology, 2002, 50, 360-366.	2.3	8
142	Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. Journal of Clinical Investigation, 2002, 109, 1261-1269.	8.2	24
143	Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. Journal of Clinical Investigation, 2002, 109, 1261-1269.	8.2	16
144	Biosynthetic Ganciclovir Triphosphate: Its Isolation and Characterization from Ganciclovir-Treated Herpes Simplex Thymidine Kinase-Transduced Murine Cells. Biochemical and Biophysical Research Communications, 2001, 289, 525-530.	2.1	11

#	Article	IF	Citations
145	Unexpected Effects of FERM Domain Mutations on Catalytic Activity of Jak3. Molecular Cell, 2001, 8, 959-969.	9.7	127
146	Lack of dominant-negative effects of a truncated Î³c on retroviral-mediated gene correction of immunodeficient mice. Blood, 2001, 97, 1618-1624.	1.4	21
147	Gene therapy for primary immune deficiencies. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 497-501.	2.3	4
148	Gene therapy for immunodeficiency. Current Allergy and Asthma Reports, 2001, 1, 407-415.	5.3	5
149	Unexpected and variable phenotypes in a family with JAK3 deficiency. Genes and Immunity, 2001, 2, 422-432.	4.1	63
150	Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 8697-8702.	7.1	137
151	Comparison of Five Retrovirus Vectors Containing the Human IL-2 Receptor Î³ Chain Gene for Their Ability to Restore T and B Lymphocytes in the X-Linked Severe Combined Immunodeficiency Mouse Model. Molecular Therapy, 2001, 3, 565-573.	8.2	20
152	Expansion of Hepatic and Hematopoietic Stem Cells Utilizing Mouse Embryonic Liver Explants. Cell Transplantation, 2001, 10, 81-89.	2.5	41
153	Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency.Defects of the gc-JAK3 signaling pathway as a model. Immunological Reviews, 2000, 178, 39-48.	6.0	97
154	Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer. Cancer Gene Therapy, 2000, 7, 574-580.	4.6	17
155	Lymphoid Development and Function in X-Linked Severe Combined Immunodeficiency Mice after Stem Cell Gene Therapy. Molecular Therapy, 2000, 1, 145-153.	8.2	59
156	In VivoCompetitive Studies between Normal and Common Î³ Chain-Defective Bone Marrow Cells: Implications for Gene Therapy. Human Gene Therapy, 2000, 11, 2051-2056.	2.7	17
157	Hierarchy of Protein Tyrosine Kinases in Interleukin-2 (IL-2) Signaling: Activation of Syk Depends on Jak3; However, Neither Syk nor Lck Is Required for IL-2-Mediated STAT Activation. Molecular and Cellular Biology, 2000, 20, 4371-4380.	2.3	35
158	Complex Effects of Naturally Occurring Mutations in the JAK3 Pseudokinase Domain: Evidence for Interactions between the Kinase and Pseudokinase Domains. Molecular and Cellular Biology, 2000, 20, 947-956.	2.3	125
159	Development of Autologous T Lymphocytes in Two Males with X-Linked Severe Combined Immune Deficiency: Molecular and Cellular Characterization. Clinical Immunology, 2000, 95, 39-50.	3.2	42
160	Molecular Modeling of the Jak3 Kinase Domains and Structural Basis for Severe Combined Immunodeficiency. Clinical Immunology, 2000, 96, 108-118.	3.2	23
161	Combined Immunodeficiencies Due to Defects in Signal Transduction: Defects of the Î³c-JAK3 Signaling Pathway as a Model. Immunobiology, 2000, 202, 106-119.	1.9	28
162	THE POTENTIAL FOR THERAPY OF IMMUNE DISORDERS WITH GENE THERAPY. Pediatric Clinics of North America, 2000, 47, 1389-1407.	1.8	11

#	Article	IF	Citations
163	JAK3-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY. Immunology and Allergy Clinics of North America, 2000, 20, 97-111.	1.9	5
164	Efficient Gene Transfer to Human Peripheral Blood Monocyte-Derived Dendritic Cells Using Human Immunodeficiency Virus Type 1-Based Lentiviral Vectors. Human Gene Therapy, 2000, 11, 1901-1909.	2.7	80
165	Gene Therapy for Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: Improved Retroviral Vectors for Clinical Trials. Acta Haematologica, 1999, 101, 89-96.	1.4	30
166	Retroviral-Mediated Transfer andExpression of the Common Gamma Chain intoHuman Hematopoietic Progenitors. Acta Haematologica, 1999, 101, 106-110.	1.4	0
167	Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskottâ€“Aldrich syndrome patients carrying â€˜nullâ€™ mutations. Gene Therapy, 1999, 6, 1170-1174.	4.5	40
168	Severe combined immune deficiencies due to defects of the common ? chain-JAK3 signaling pathway. Seminars in Immunopathology, 1998, 19, 401-415.	4.0	18
169	Gene therapy of primary immunodeficiencies. Seminars in Immunopathology, 1998, 19, 493-508.	4.0	2
170	Development of Autologous, Oligoclonal, Poorly Functioning T Lymphocytes in a Patient With Autosomal Recessive Severe Combined Immunodeficiency Caused by Defects of the Jak3 Tyrosine Kinase. Blood, 1998, 91, 949-955.	1.4	37
171	Development of Autologous, Oligoclonal, Poorly Functioning T Lymphocytes in a Patient With Autosomal Recessive Severe Combined Immunodeficiency Caused by Defects of the Jak3 Tyrosine Kinase. Blood, 1998, 91, 949-955.	1.4	1
172	Interleukin-4 Signaling in B Lymphocytes from Patients with X-linked Severe Combined Immunodeficiency. Journal of Biological Chemistry, 1997, 272, 7314-7319.	3.4	26
173	Retroviral Transfer of AcidÎ±-Glucosidase cDNA to Enzyme-Deficient Myoblasts Results in Phenotypic Spread of the Genotypic Correction by Both Secretion and Fusion. Human Gene Therapy, 1997, 8, 1555-1563.	2.7	38
174	Structural and Functional Basis for JAK3-Deficient Severe Combined Immunodeficiency. Blood, 1997, 90, 3996-4003.	1.4	138
175	Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. Journal of Clinical Immunology, 1997, 17, 431-447.	3.8	45
176	Signaling via IL-2 and IL-4 in JAK3-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways. Immunity, 1996, 5, 605-615.	14.3	120
177	THE USE OF GENE THERAPY FOR IMMUNODEFICIENCY DISEASE. Immunology and Allergy Clinics of North America, 1996, 16, 683-726.	1.9	3
178	In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.. Journal of Experimental Medicine, 1996, 183, 2687-2692.	8.5	71
179	Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature, 1995, 377, 65-68.	27.8	864
180	Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. Human Gene Therapy, 1995, 6, 813-819.	2.7	137

#	Article	IF	Citations
181	Application of Molecular Analysis to Genetic Counseling in the Wiskottâ€“Aldrich Syndrome (WAS). DNA and Cell Biology, 1993, 12, 645-649.	1.9	4
182	Molecular Basis of Severe Combined Immunodeficiency: Lessons from Cytokine Signaling Pathways. , 0, , 279-305.		0